Back to Awarded Treatment Trials
Awarded Trial: 09T-001
Grant ID
09T-001
Illness
Schizophrenia
Primary Drug/Intervention
Allopurinol
Primary Dosage
300 mg/b.i.d.
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Weiser
Sample Size
260
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
N/A
Results
Both groups showed improvement in the PANSS and in clinical and cognitive measures. No difference was observed between groups in primary or secondary outcome measures. These findings do not support allopurinol as a treatment for schizophrenia.
Publication
Weiser M, Gershon AA, Rubinstein K, Petcu C, Ladea M, Sima D, Podea D, Keefe RS, Davis JM. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2012 Jun;138(1):35-8.
Link
http://www.ncbi.nlm.nih.gov/pubmed/22483162
PI Name
Mark Weiser
Degree
MD
Center
Psychiatric Outpatient Clinic
Institution
Sheba Medical Center
Address
Sheba Medical Center
City or Town
Tel-Hashomer
State or Province
N/A
Zip or Postal Code
52621
Country
Israel
Email Address
m.weiser@netvision.net.il